Urg.. tradingview decided to hide a lot of my previous idea because I didn't go pro, what a scam.
If you like my charts and would like to support me going pro for $12.95, please msg me so i can keep sending out these ideas weekly.
Open position at $182
Stop loss at $180
Take profit at $187
Why this play?
Gwph had a pretty good earning but got...
GWPH is on a nice uptrend into earnings despite the negative price action within the cannabis stocks. Analysts have a average price target of $188 on the stock with a consensus BUY rating. This may be a little risky into earnings but it looks destined to break the $180.50 price resistance.
GW Pharmaceuticals Plc is a biopharmaceutical...
The Bulls are getting trend resumption after testing the EMA and filling the buy climax gap at $150. Prices will likely reach a new all time high soon. There are signs of profit taking around the new all time high (sideways for past 8 weeks). A reversal down soon could become a second entry for the larger wedge reversal. If there is another buy climax prices...
A friend on Tradingview gave me a tip the other day when he said "GWPH is cheap right now. Temporary health industry dip. Great long term stock. " Well I finally got off my lqzy a$$ and looked it up today to find an evaluation that read as follows: ...
Despite the rally this week GWPH has lagged the market, this is due to the Cronas downgrade which has hit the entire sector. A pullback is expected and overdue to gain strength in this stock is much less speculative than others in the group with no real financials.
GWPH looks like it could have a at least a nice retracement at a worst case scneario and a juicy trade at a better scneario if the S&P does have a bit of a crash. I will be shorting this at current price and taking profit at green, I would like to re add at my elliot wave idea, lets see how this one ends up :)
long entry from $100; PT1 $125 PT2 $143
Q1 2019 - FDA meeting outcome on Sativex;
Sativex (nabiximols) is an oromucosal spray of a formulated botanical extract of cannabis
that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio
Approved in >25 countries outside of the U.S. for the treatment of spasticity...
Q4 Pullback was expected, not a big deal; Stock price elevated because of news and same old pump and dump. Epidiolex didn't ship until November 1st.
3 Positive Phase 3 from Sativex - FDA meeting for regulatory pathway to U.S. expected in December.
Resumed @ Piper Jaffray on Nov 5th as overweight; The Street updated to sell after the drop; Market edge on...